Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Ph II CHOP+Velcade in Mediastinal LBCL
- Conditions
- Non-Hodgkin's Lymphoma
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT00361621
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders
- Conditions
- Severe Aplastic AnemiaGenetic DisorderImmunodeficiency Syndrome
- Interventions
- Procedure: Allogeneic Bone Marrow TransplantationDrug: CyclophosphamideDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisDrug: Mycophenolate MofetilProcedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell TransplantationDrug: SirolimusDrug: TacrolimusRadiation: Total-Body Irradiation
- First Posted Date
- 2006-08-01
- Last Posted Date
- 2021-01-26
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00358657
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸The Children's Hospital at TriStar Centennial, Nashville, Tennessee, United States
Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies
- Conditions
- LeukemiaMyelodysplastic Syndromes
- Interventions
- Drug: CyclophosphamideBiological: Donor T cells
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 14
- Registration Number
- NCT00356928
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
- Conditions
- NeuroblastomaUnspecified Childhood Solid Tumor, Protocol SpecificLymphomaCentral Nervous System Tumor, PediatricLeukemiaSarcoma
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 101
- Registration Number
- NCT00357500
- Locations
- 🇺🇸
Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇺🇸St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
- Conditions
- LeukemiaMyelodysplastic Syndromes
- Interventions
- Biological: aldesleukinBiological: filgrastimBiological: natural killer cell (NK) therapyDrug: cyclophosphamideDrug: cyclosporineDrug: fludarabine phosphateDrug: methylprednisoloneDrug: mycophenolate mofetilProcedure: Umbilical Cord Blood Transplantation (UCBT)Radiation: Total body irradiation (TBI)
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 16
- Registration Number
- NCT00354172
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
- Conditions
- Adult RhabdomyosarcomaChildhood Botryoid-Type Embryonal RhabdomyosarcomaRhabdomyosarcomaSarcomaStage I Adult Soft Tissue Sarcoma AJCC v7Stage III Adult Soft Tissue Sarcoma AJCC v7Localized Childhood Soft Tissue SarcomaChildhood Alveolar RhabdomyosarcomaChildhood Embryonal RhabdomyosarcomaStage II Adult Soft Tissue Sarcoma AJCC v7
- Interventions
- Drug: CyclophosphamideBiological: DactinomycinOther: Laboratory Biomarker AnalysisDrug: Irinotecan HydrochlorideOther: Questionnaire AdministrationRadiation: Radiation TherapyDrug: Vincristine Sulfate
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 481
- Registration Number
- NCT00354835
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Kaiser Permanente Downey Medical Center, Downey, California, United States
Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant
- Conditions
- Aplastic Anemia
- Interventions
- Radiation: total-body irradiationDrug: cyclophosphamideBiological: anti-thymocyte globulinDrug: cyclosporineProcedure: umbilical cord blood transplantationDrug: mycophenolate mofetilProcedure: bone marrow aspirationGenetic: DNA analysisBiological: filgrastim
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2011-01-05
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00354419
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
- Conditions
- Sarcoma
- Interventions
- Biological: dactinomycinDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: ifosfamideDrug: irinotecan hydrochlorideDrug: vincristine sulfateProcedure: conventional surgeryRadiation: radiation therapyBiological: filgrastim
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 109
- Registration Number
- NCT00354744
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, United States
TBI Dose De-escalation for Fanconi Anemia
- Conditions
- Fanconi Anemia
- Interventions
- Drug: CyclophosphamideDrug: FludarabineProcedure: Total Body IrradiationProcedure: Bone Marrow TransplantationDrug: Mycophenolate MofetilDrug: Sirolimus
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 83
- Registration Number
- NCT00352976
- Locations
- 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
- Conditions
- Hodgkin's Lymphoma
- Interventions
- Drug: Adriamycin®Drug: VinblastineDrug: Nitrogen MustardDrug: CyclophosphamideDrug: VincristineDrug: BleomycinDrug: EtoposideDrug: PrednisoneBiological: G-CSFProcedure: Radiotherapy
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT00352027
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.